Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 1783 results found since Jan 2013.
Identifying the Optimal Age for Herpes Zoster Vaccination - Yichang City, Hubei Province, China, 2017-2019
China CDC Wkly. 2022 Jul 22;4(29):631-634. doi: 10.46234/ccdcw2022.137.ABSTRACTWHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: Herpes zoster (shingles) is a common skin condition in older adults, which usually presents as a painful rash with blisters. Vaccination is the most effective method to prevent shingles. However, there is not sufficient population-based epidemiological data in China to optimize the timing of zoster vaccination.WHAT IS ADDED BY THIS REPORT?: Clustering analyses of population-wide epidemiological data from the Healthcare Big Data Platform in Yichang, China showed that the average annual zoster incidence is ...
Source: Herpes - August 3, 2022 Category: Infectious Diseases Authors: Meiying You Tianqi Wang Miaomiao Wang Wei Jiang Jing Jiang Xudong Li Yuehua Hu Dapeng Yin Source Type: research
Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation
CONCLUSION: VZV booster vaccination increases VZV-specific IgG titers and percentage VZV-specific memory T-cells for at least 1 year both in ESRD patients and healthy controls. VZV-specific memory B cells significantly increased in patients up to 3 months after vaccination. Prophylactic VZV booster vaccination prior to transplantation could reduce HZ incidence and severity after transplantation.PMID:35935972 | PMC:PMC9352887 | DOI:10.3389/fimmu.2022.927734
Source: Herpes - August 8, 2022 Category: Infectious Diseases Authors: Marcia M L Kho Willem Weimar S Reshwan K Malahe Joke M Zuijderwijk Ronella de Kuiper Marieken J Boer-Verschragen Annemiek A van der Eijk Dennis A Hesselink Marlies E J Reinders Nicole M van Besouw Source Type: research
Vaccination coverage of patients with type 2 diabetes mellitus: Challenging issues from an outpatient secondary care setting in Greece
CONCLUSIONS: Vaccination rates of patients with T2D show an increasing trend, especially for influenza and S. pneumoniae, although the one for S. pneumoniae was low. Older people seem more prone to vaccination, the one for herpes zoster was low with infected patients remaining unvaccinated while significantly low coverage was observed for other VPDs. The findings are important to improve effectiveness of preventative services.PMID:35979460 | PMC:PMC9376377 | DOI:10.3389/fpubh.2022.921243
Source: Herpes - August 18, 2022 Category: Infectious Diseases Authors: Georgios Galanos Helen Dimitriou Angelos Pappas Chrysoula Perdikogianni Emmanouil K Symvoulakis Emmanouil Galanakis Christos Lionis Source Type: research
Seropositivity, Risks, and Morbidity From Varicella-Zoster Virus Infections in an Adult PWH Cohort From 2000-2020
CONCLUSIONS: Despite ART and vaccines for chickenpox and shingles, VZV still caused significant costs and morbidity for PWH, occurring at younger ages and often as encephalitis/meningitis. Supporting ART adherence may reduce VZV illness and hospitalization costs in PWH, and the cost-effectiveness of expanding shingles vaccine use warrants further study.PMID:36004318 | PMC:PMC9394766 | DOI:10.1093/ofid/ofac395
Source: Herpes - August 25, 2022 Category: Infectious Diseases Authors: Jason Zou Hartmut B Krentz Raynell Lang Brenda Beckthold Kevin Fonseca M John Gill Source Type: research
Baculovirus Display of Varicella-Zoster Virus Glycoprotein E Induces Robust Humoral and Cellular Immune Responses in Mice
Viruses. 2022 Aug 16;14(8):1785. doi: 10.3390/v14081785.ABSTRACTVaricella-zoster virus (VZV) is the causative agent of varicella and herpes zoster (HZ) and can pose a significant challenge to human health globally. The initial VZV infection-more common in children-causes a self-limiting chicken pox. However, in later life, the latent VZV can become reactivated in these patients, causing HZ and postherpetic neuralgia (PHN), a serious and painful complication. VZV glycoprotein E (gE) has been developed into a licensed subunit vaccine against HZ (Shingrix). However, its efficacy relies on the concomitant delivery of a robust ...
Source: Herpes - August 26, 2022 Category: Infectious Diseases Authors: Wenhui Xue Tingting Li Sibo Zhang Yingbin Wang Minqing Hong Lingyan Cui Hong Wang Yuyun Zhang Tingting Chen Rui Zhu Zhenqin Chen Lizhi Zhou Rongwei Zhang Tong Cheng Qingbing Zheng Jun Zhang Ying Gu Ningshao Xia Shaowei Li Source Type: research
Herpes Zoster Vaccination Rates in Hematological and Oncological Patients-Stock Taking 2 Years after Market Approval
CONCLUSION: Despite clear recommendations and a pressing need in the high-risk population of hematological and oncological patients, the vast majority of patients are still left without vaccine protection against Herpes zoster by Shingrix®.PMID:36011181 | PMC:PMC9408327 | DOI:10.3390/healthcare10081524
Source: Herpes - August 26, 2022 Category: Infectious Diseases Authors: Til Ram ón Kiderlen Katrin Trostdorf Nicola Delmastro Arne Salomon Maike de Wit Mark Reinwald Source Type: research
Spectrum of Mucocutaneous Reactions to COVID-19 Vaccination: A Report from a Web-Based Study from India
CONCLUSION: Majority reported mild and self-limiting reactions. This outcome should not discourage the common man in getting vaccinated.PMID:36092222 | PMC:PMC9455097 | DOI:10.4103/ijd.ijd_893_21
Source: Herpes - September 12, 2022 Category: Infectious Diseases Authors: Abheek Sil Deepak Jakhar Anupam Das Soumya Jagadeesan Sujala Sacchidanand Aradhya Source Type: research
Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis
CONCLUSIONS: Though some ESRD patients on HD had local and systemic AEs after first-dose vaccination, the clinical significance of these symptoms was minor. Our study confirmed the safety profile of ChAdOx1 nCoV-19 in HD patients and presented a new viewpoint on vaccine-related AEs. The SCCS analysis did not find an elevated risk of VAT at 1 month following vaccination. Apart from VAT, other vaccine-related AEs, irrespective of local or systemic symptoms, had minor clinical significance on safety issues. Nonetheless, further coordinated, multi-center, or registry-based studies are needed to establish the causality.PMID:360...
Source: Herpes - September 9, 2022 Category: Infectious Diseases Authors: I-Ning Yang Chin-Li Lu Hung-Jen Tang Yu-Chi Kuo Li-Hwa Tsai Kuan Chieh Tu Jhi-Joung Wang Chih-Chiang Chien Source Type: research
Spectrum of Mucocutaneous Reactions to COVID-19 Vaccination: A Report from a Web-Based Study from India
CONCLUSION: Majority reported mild and self-limiting reactions. This outcome should not discourage the common man in getting vaccinated.PMID:36092222 | PMC:PMC9455097 | DOI:10.4103/ijd.ijd_893_21
Source: Herpes - September 12, 2022 Category: Infectious Diseases Authors: Abheek Sil Deepak Jakhar Anupam Das Soumya Jagadeesan Sujala Sacchidanand Aradhya Source Type: research
Modeling the Impact of Exogenous Boosting and Universal Varicella Vaccination on the Clinical and Economic Burden of Varicella and Herpes Zoster in a Dynamic Population for England and Wales
Vaccines (Basel). 2022 Aug 28;10(9):1416. doi: 10.3390/vaccines10091416.ABSTRACTUniversal varicella vaccination (UVV) in England and Wales has been hindered by its potential impact on exogenous boosting and increase in herpes zoster (HZ) incidence. We projected the impact of ten UVV strategies in England and Wales on the incidence of varicella and HZ and evaluated their cost-effectiveness over 50 years. The Maternal-Susceptible-Exposed-Infected-Recovered-Vaccinated transmission model was extended in a dynamically changing, age-structured population. Our model estimated that one- or two-dose UVV strategies significantly red...
Source: Herpes - September 23, 2022 Category: Infectious Diseases Authors: Oluwaseun Sharomi Ilaria Xausa Robert Nachbar Matthew Pillsbury Ian Matthews Tanaz Petigara Elamin Elbasha Manjiri Pawaskar Source Type: research
An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination
Conclusions SIT has already been demonstrated to be safe and effective against five different families of viruses, hepatitis A virus, hepatitis B virus, hepatitis C virus, SARS-CoV-2, and herpes zoster virus. The R903/78 drug candidate is simple to manufacture and easy to administer in an outpatient setting. The expected cost of SIT will be affordable even in resource-limited countries.PMID:36176842 | PMC:PMC9511982 | DOI:10.7759/cureus.28467
Source: Herpes - September 30, 2022 Category: Infectious Diseases Authors: Tibor Bakacs Volker Sandig Imre Kovesdi Source Type: research
